ATOS8:45 AMAtossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate UpdateEnrollment • Phase 2Enrollment completion Tue, Jun 30, 2026atossatherapeutics.com
ATOS8:30 AMAtossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Canceratossatherapeutics.com
ATOS8:30 AMAtossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancersatossatherapeutics.com